The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hikal Ltd promoter entities Shri Rameshwara Investment Pvt Ltd and Shri Badrinath Investment Pvt Ltd have merged into Castilia Life Sciences Pvt Ltd under a Scheme of Amalgamation approved by the Regional Director on 18 November 2025, effective from 3 December 2025. As a result, the Hikal shares earlier held by the two transferor companies (totalling 1,02,31,914 shares, 4.52%) have now vested in Castilia. Filing is made under Regulation 10(7)/10(1)(d)(iii) of the Takeover Code to claim exemption from open offer triggered under Regulations 4 and 5. Total promoter group shareholding (Acquirer + PAC) remains unchanged at 1,27,20,100 shares (10.31%) before and after, since all three entities had identical mirror shareholding - meaning there is no change in ultimate ownership or control.
No real change for retail shareholders - this is purely a corporate restructuring within the promoter family. Promoter holding and control remain exactly the same, so there is no open offer obligation and no change in voting power. The stock is unlikely to see any material impact.